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Recent advances in genetics have highlighted several regions and candidate genes
associated with primary Sjögren’s syndrome (SS), a systemic autoimmune epithelitis that
combines exocrine gland dysfunctions, and focal lymphocytic infiltrations. In addition to
genetic factors, it is now clear that epigenetic deregulations are present during SS and
restricted to specific cell type subsets, such as lymphocytes and salivary gland epithelial
cells. In this study, 72 single nucleotide polymorphisms (SNPs) associated with 43 SS
gene risk factors were selected from publicly available and peer reviewed literature for
further in silico analysis. SS risk variant location was tested revealing a broad distribution
in coding sequences (5.6%), intronic sequences (55.6%), upstream/downstream genic
regions (30.5%), and intergenic regions (8.3%). Moreover, a significant enrichment of
regulatory motifs (promoter, enhancer, insulator, DNAse peak, and expression quanti-
tative trait loci) characterizes SS risk variants (94.4%). Next, screening SNPs in high
linkage disequilibrium (r20.8 in Caucasians) revealed 645 new variants including 5 SNPs
with missense mutations, and indicated an enrichment of transcriptionally active motifs
according to the cell type (B cells>monocytes>T cellsA549). Finally, we looked
at SS risk variants for histone markers in B cells (GM12878), monocytes (CD14+) and
epithelial cells (A548). Active histone markers were associated with SS risk variants
at both promoters and enhancers in B cells, and within enhancers in monocytes. In
conclusion and based on the obtained in silico results that need further confirmation,
associations were observed between SS genetic risk factors and epigenetic factors and
these associations predominate in B cells, such as those observed at the FAM167A–BLK
locus.
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Introduction
Primary Sjögren’s syndrome (SS) is a systemic autoimmune
epithelitis affecting exocrine glands, such as salivary and lacrimal
glands (1). The clinical manifestations of SS include dry mouth
(xerostomia), dry eyes (keratoconjunctivitis sicca), systemic fea-
tures, and patients have a 20- to 40-fold increased risk of devel-
oping lymphoma (2–4). Histological examination shows focal
and peri-epithelial T and B cell infiltration plus macrophages in
exocrine glands and parenchymal organs, such as kidney, lung,
and liver (5). SS is characterized by the presence of circulating
autoantibodies (Ab) against the sicca syndrome (SS)A/Ro and
SSB/La ribonucleoprotein particles (6).
It is estimated that there are over 120 million single nucleotide
polymorphisms (SNPs) in the human genome (NCBI dbSNP
database, Build 143) and, among them, hundreds are disease
risk variants for autoimmune diseases (AID) with the particu-
larity that they are for the vast majority excluded from protein-
coding regions (exon) and present within regulatory areas (7,
8). Regulatory SNPs control genes through an effect on (i) the
transcriptional machinery when present within a gene regulatory
region [promoter, enhancer, insulator (a gene regulatory element
that blocks interaction between enhancers and promoters), and
expression quantitative trait loci (eQTL)], (ii) the spliceosomal
complex formation that controls intron excision, (iii) the activa-
tion of mRNA non-sense-mediated decay (NMD), and (iv) the
control of messenger RNA stability throughmicroRNA (30-UTR).
In SS, the list of genetic variations is growing with the particularity
that the odds ratio (OR) is usually modest (OR< 1.5) with the
exception of theHLAgenes that have a significantOR (usually>2)
(9). The associated risk genes analysis supports immunopatho-
logical pathways in SS, such as antigen presentation, cytokine
signaling, and the NF-κB pathway (10). The characterization of
regulatory SNPs in SS remains to be established.
In SS, several arguments support a role for epigenetic deregu-
lation in disease initiation and progression (11, 12). The first clue
was that two drugs, procainamide and hydralazine, induced SS in
humans by blocking DNA methylation (13). Moreover, defects in
DNA methylation characterize T cells, B cells, and salivary gland
epithelial cells from SS patients (14–16), and such defects were
associated with the expression of genes usually repressed by DNA
methylation, such as transposons and miRNAs in salivary glands
from SS patients (17, 18). Last, but not least, histone epigenetic
markers and ribonucleoprotein post-translational modifications
are immunogenic leading to autoAb production (14).
Accordingly, the aim of this work was to test the association
between genetic and epigenetic determinants in SS. In the fol-
lowing, we pursue a two-staged analysis. First, we characterized a
large panel of SS risk variants to reveal that they are predominantly
present within regulatory elements. Second, we further explored
the striking associations of those regulatory elements with cellular
specificity and particularly in immune cells.
Materials and Methods
SS Genetic Risk Factors
Data mining based on peer reviewed literature information
(PubMed) and publicly available databases (centralgwas.org)
served in the compilation of a list of 43 gene risk factors and
their reported variants (n= 72) in SS (Table S1 in Supplementary
Material) (19–49). The number of SS patients and controls were
also reported as well as the OR average (95%), when available.
The gene list used in this study was manually updated further
to include gene function, SNP number (dbSNP database), and
genomic location according to the human genome reference
GRCh38. Genetic variants and their observed associations with
clinical and functional phenotype were submitted to The National
Center for Biotechnology Information (NCBI) ClinVar database1.
The gene list was tested with the FatiGO web interface AmiGO22
for functional enrichment.
Functional/Regulatory Genome Annotation Data
The variant effect predictor (VEP) tool3 was used to deter-
mine the location of the variants (exon, intron, 50/30-UTR,
Up/Downstreamgenic sequence, and intergenic section) and their
consequences [missense, non-coding transcript, splice donor vari-
ant, and target of non-sense-mediated mRNA decay (NMD)].
Assessment of the SNPs functional relevance was further
completed by requesting Regulome DB V1.14, and HaploRegV25,
data bases (50, 51) for promoter [RNA polymerase II (Pol II)
binding], enhancer (H3K27Ac, H3K36me3, and/or H3K27me3
binding in the absence of Pol II binding), insulator [CCCCTC-
binding factor (CTCF)], transcription factor (TF) binding, DNase
peak, and eQTL.
Linkage Disequilibrium
Following SNP selection, the HaploRegV2 web portal was used
to identify SNPs in linkage disequilibrium (LD, R2 0.80) in
Europeans from the 1000 genome project using a maximum
distance between variants of 200 kb in order to cover the enhancer
elements (51).
Statistical Analysis
Pearson’s Chi-squared test with Yate’s continuity correction, when
appropriate, was used to evaluate the significance of differ-
ences between the regulatory motifs and the histone chromatin
immunoprecipitation (ChIP) experiments. A probability (P) of
<0.05 was considered significant.
Results
Autoimmune-Related Genes Associated with SS
A list of 43 SS-associated gene risk factors corresponding to 72
SNPs, referred to as SS risk variants, was extracted from the
scientific literature (Figure 1). Among the risk factors, half (36/72)
were associated with another AID (systemic lupus erythemato-
sus, rheumatoid arthritis, systemic sclerosis, inflammatory bowel
disease, autoimmune thyroiditis disease, insulin-dependent dia-
betes, primary biliary cirrhosis, autoimmune hepatitis), allergy,
infections, and cancer, including B/T cell lymphomas. This partial
1http://www.ncbi.nlm.nih.gov/clinvar
2http://amigo2.geneontology.org
3http://www.ensembl.org
4http://regulome.stanford.edu
5http://www.broadinstitute.org
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FIGURE 1 | Schematic diagram representing the analysis strategy.
SS-associated risk variants were obtained from peer reviewed scientific
literature, and their location determined. Next, they were tested for the
enrichment of binding factors and cellular specificity. Presence of single
nucleotide polymorphisms (SNP) in high linkage disequilibrium (LD) was also
assessed.
overlap suggests that both common and distinct genetic traits are
present in SS and equally distributed.
Variant Location
Next, we used the VEP predictor tool in order to test the
location of the different variants (Figure 2). Applied to the
72 SS risk variants, the VEP tools identified 4/72 (5.6%)
exonic variants with missense mutations (IL17F, rs763780; MBL2,
rs1800450; PTPN22, rs2476601; and TNFA1P3, rs2230926), and
40/72 (55.6%) intronic variants including an alternative splice
donor variant (IRF5, rs2004640) and 4 variants that were pre-
dicted as targets of non-sense-mediated mRNA decay (NMD:
ICA1, rs17143355; SLC25A40, rs10276819; STAT1, rs13005843;
and TNIP1, rs6579837). Moreover, two 50-UTR variants (CD14,
rs2569190; and NCR3, rs11575837), one 30-UTR variant (IL10,
rs3024498), 12/72 (16.7%) upstream genic variants, 7/72 (9.7%)
downstream genic variants, and 6/72 (8.3%) intergenic variants
(>10 kb) were also observed.
Regulatory Regions and DNA Binding Molecules
We then used a combination of three tools based on information
from the ENCODE program (VEP) and from both the ENCODE
and the Roadmap Epigenome programs (RegulomDB and Hap-
loReg v2) to determine whether SS risk variants are likely to
be within promoters, enhancers, or insulators. These regula-
tory motifs were defined according to the available ChIP results
from multi-cell analysis showing 21/72 (29.2%) promoters, 41/72
(56.9%) enhancers, and 5/72 (6.9%) insulators. Of particular note,
within the four SNPs with missense mutations, one promoter
and two insulators were detected (Figure 3). Moreover, 34/72
(47.2%) DNase hypersensitive regions (DNase peak) and 12/72
(16.7%) eQTL were recovered. Looking specifically at promoters
and enhancers, data from ChIP experiments revealed that NF-
κB (n= 5), STATs (n= 3), and EGR-1 (n= 3) were predominant
in promoters, and NF-κB (n= 3) in enhancers. For the remain-
ing 5/72 (6.9%) SNPs, no regulatory functions were assigned
which is significantly lower than the expected rate of 56.2%
(P< 10 6) (50).
Genes in High Linkage Disequilibrium
In order to improve the analysis, we used the HaploReg v2 tool
to include 645 new SNPs that were identified to be in high LD
with the 72 annotated SNPs (Table 1). This tool identifies 34
new genes, including one microRNA (Mir4752), five SNPs with
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FIGURE 2 | Occurrences of SS risk variants according to the protein-coding gene location.
FIGURE 3 | Regulatory SS risk variants were subdivided into three
groups: promoters (polymerase II binding), enhancers (H3k27Ac,
H3k36me3, and/or H3k7me3 binding), and insulators (CTCF binding).
Regulatory SS risk variants were further located according to the protein-coding
gene, and the predominant transcription factor associated with each SS risk
variant is indicated (NF-κB, STATs, and Egr1).
missense mutations (rs1041981 in LTA; rs78957773 in MCCD1,
rs2230539 in PKN1, and rs52817781 plus rs2233290 in TNIP1),
and indicated an overall 15.8-fold enrichment of enhancers in
human embryonic cells (H1; P= 0.0001) and 4.9-fold enrichment
of enhancers in theGM12878 EBV-transformed lymphoblastoid B
cell line (P= 0.0014). A significant enrichment of transcription-
ally active sites, identified by DNAse enrichment analysis, was
observed in the SNP set with a 21-fold increase in GM12878
lymphoblastoid B cells (P< 10 6), 10.8-fold increase in CD14+
monocytes (P= 0.00002), 9.2-fold increase in CD20+ B cells
(P= 0.001), 8.2- to 8.5-fold increase in T cells (P< 0.005), and
5.7-fold increase in the A549 epithelial cell line (P= 0.005).
Moreover, gene ontology biological process analysis (AmiGO2)
identified “regulation of immune response” (P= 2.16 10 18
and 9.2 10 17), “positive regulation of cytokine production”
(P= 1.56 10 11 and 1.22 10 13), “response to molecule of
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TABLE 1 | Gene risk factors associated with primary Sjögren’s syndrome
(SS).
SS gene risk factors extracted from the literature
BAK1, BCL2, BLK, C4A, CCL2, CD14, CD40, CD40LG, CHRM3, CXCR5, EBF1,
FAM167A, GTF2I, HLA DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, ICA1, IKBKE,
IL10, IL12A, IL17F, IL21, IRF5, LILRA3, LTA*, MBL2, NCR3, NFKB1, OR2B11,
PKN1*, PTPN22, SLC25A40, STAT1, STAT4, TNF, TNFA1P3, TNFSF13B,
TNIP1*, TNPO3, TNFSF4, Trim21
New genes in high linkage disequilibrium
ABCB1, AC053545.3, ADAD1, AF213884.2, APBB3, ATP6V1G2,
ATP6V1G2-DDX39B, BTNL2, C6orf10, CCL11, CCL7, CTD-2049J23.2, DBF4,
GGNBP1, HCG23, HLA-DPA1, IL2, KIAA1109, MCCD1*, Metazoa_SRP,
MIR4752, NDUFA2, NFKBIL1, PTGER1, RP11-10J5.1, RP11-356I2.2,
RP11-356I2.4, RP3-527F8.2, RP5-998H6.2, RSBN1, RUNDC3B, SLC25A40,
snoU13, XXbac-BPG254F23.7
Bold missense mutations.
*Missense mutations detected by linkage disequilibrium.
bacterial origin” (P= 4.9 10 7 and 6.2 10 9), and “cellular
response to interferon” (P= 1.82 10 7 and 1.86 10 7) as the
most significant functions associated with the SS gene risk factors
tested alone or associated with the genes revealed by the LD
analysis, respectively.
Cell Type-Specific Analysis Revealed Activated
Enhancer and Promoter Histone Markers at SS
Risk Variants in B Cells
To further explore cell type specific activation in promoters
and enhancers at SS risk variants and according to the critical
role played in the disease by epithelial cells, lymphocytes, and
macrophages, we selected from the 18 ENCODE available cells:
the human lung adenocarcinoma cell line A549 for epithelial
cells, the GM12878 lymphoblastoid cells for B cells, and the
peripheral blood CD14+ monocytes for macrophages. For these
three cell types, we mapped SS risk variants to markers of active
promoters (H3K4me2, H3K4me3, and H3K9Ac), and to markers
of active enhancers (H3K36me3 andH3K4me1) (52). In addition,
H3K27Ac was selected as a marker of activity, and H3K27me3 as
an inactive marker of enhancers.
As shown in Figure 4A and with regards to the 21 promoter
SS risk variants, the three active promoter markers (H3K4me2,
H3K4me3, and H3K9Ac) were significantly enriched in B cells
(GM12878) in contrast to the epithelial cells (A549) and mono-
cytes (0.01< P< 0.0006, Chi square with Yate’s correction). The
active marker H3K27Ac was enriched in B cells andmonocytes in
contrast to epithelial cells (P= 0.0001 and P= 0.02, respectively).
The same analysis was performed with the 41 enhancer SS risk
variants (Figure 4B) revealing an enrichment of the enhancer
active marker H3K36me3 in both B cells and monocytes in con-
trast to A459 cells (P= 0.02 and P= 0.005, respectively). The
active marker H3K27Ac was enriched in B cells (P= 0.0001), and,
although not significant, there is a trend for a monocyte enrich-
ment in contrast to epithelial cells. In summary, these findings
highlight the critical role of epigenetic factors in B cells to control
both promoter and enhancer SS risk variants, and in monocytes
to control enhancer SS risk variants.
FAM167A–BLK Locus
In order to validate our observations, and based on three reports,
including the genome wide association study (GWAS) per-
formed by Lessard et al., in 395 patients with SS and 1975 con-
trols from European origins (31, 35, 41), the FAM167A–BLK
locus (Chr 8:11421463-11564604) was selected to position the 8
FAM167A–BLK SS risk variants plus two 50-UTR variants selected
from the LD analysis and previously identified as lupus risk vari-
ants (53). These two SNPs are in high LD with 4/8 SS risk variants
[rs922483 is in high LD with rs2736340 (r2= 0.81), rs13277113
(r2= 0.83), and rs2736345 (r2= 0.96); and rs2250788 is in high
LD with rs2254546 (r2= 0.98)]. As shown in Figure 4C, the
10 selected SNPs were positioned in the FAM167A–BLK locus
revealing three groups. The first group contains an isolated SNP
(rs12549796) that was present in an intronic part of the FAM167A
gene. A second group (n= 7)was present in the vicinity of the BLK
promoter and exon 1, and a third group (n= 2) was present ~35 kb
downstream BLK promoter.
Next, as revealed by querying the Ensembl database using
H3K27Ac to mark active promoters and enhancers, SNPs were
positioned within 9/10 H3K27Ac active motifs in B cells
(GM12878), which is in contrast to 2/10H3K27Ac activemotifs in
monocytes, and none in epithelial cells. Such associations between
genetic and epigenetic factors within regulatory elements in B cells
for the FAM167A–BLK locus were further reinforced by using
the RegulomeDB tool that summarizes results from the ENCODE
and Epigenetic Roadmap programs. As indicated Table 2, the
RegulomeDB tool supports that SS risk factors at FAM167A–BLK
locus would predominantly affect B cells (lymphoblastoid and
naive B cells) and, to a lesser extent, monocytes, T cells (naïve,
TH2, and Treg), mesenchymal stem cells, and fibroblasts.
Discussion
Primary SS is an autoimmune disease with a genetic basis in
which at least 40 gene risk factors may be involved, including
BLK, IRF5, STAT4, and the HLA locus. However, these genetic
risk factors alone cannot explain all of the disease risk factors
and, in particular, environmental risk factors (e.g., viruses, hor-
mones : : :) that are likely to play a critical role in the process of the
disease. Given the complexity of the disease, epigenetic analyses
are conducted to provide new insights into the disease as DNA
methylation patterns, chromatin structures, and microRNA are
influenced both by the genetic machinery and by environmen-
tal factors (13, 54, 55). The primary role of the epigenome is
to regulate, in a cell-specific manner, cellular development, and
differentiation and such effects vary between individuals with age
as revealed by testing identical twins (56), or between smokers
and non-smokers (57). Furthermore, genetic variants and, in par-
ticular, non-coding and regulatory SNPs can influence cell type
specific regions marked by accessible regions, thus opening new
perspectives to better characterize disease risk factors and cell
types contributing to the diseases whichwas the aim of the present
in silico analysis.
Applied to SS, such strategy was fruitful in suggesting the exis-
tence of associations between genetic and epigenetic alterations
in the setting of the disease. Indeed, a cell-specific overlap
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FIGURE 4 | Analysis of histone modifications in the promoters (A) and
enhancers (B) of SS risk variants within A549 epithelial cells, B cell
lymphobastoid GM12878 cells, and CD14+ monocytes. (C) In the
lymphoblastoid GM12878 B cell line, SS genetic variants and the active histone
markers H3k27Ac are co-localized in and around the FAM167A–BLK locus
(http://www.ensembl.org).
TABLE 2 | Summary of the cell type enrichment markers for FAM167-BLK variants according to the RegulomeDB prediction web tool.
SNP Promoter (histone markers) Enhancer (histone markers) Open chromatin (DNase) eQTL Pol II (ChIP-Seq)
rs12549796 No Mesenchymal stem cells Fibroblast No No
rs7812879 No B lymphoblastoid, B cells,
monocytes
No B lymphoblastoid No
rs2254546 No B cells No B lymphoblastoid No
rs2736340 No B cells No B lymphoblastoid,
monocytes
No
rs13277113 B lymphoblastoid B cells, monocytes B lymphoblastoid,
B cells
B lymphoblastoid No
rs922483 B lymphoblastoid, B cells,
T cells, monocytes
Fibroblast B lymphoblastoid,
B cells, TH2, Treg
B lymphoblastoid B lymphoblastoid
rs2250788 B lymphoblastoid, B cells,
T cells, monocytes
Fibroblast B lymphoblastoid,
B cells
No B lymphoblastoid
rs2736345 B lymphoblastoid, B cells,
T cells
Fibroblast, Mesanchymal
stem cells
B lymphoblastoid,
B cells, TH2
B lymphoblastoid B lymphoblastoid
rs12677843 No No No No No
rs2729935 No B lymphoblastoid, B cells No No No
exists between identified SS risk variants and the regulatory
switches found by the ENCODE program, thus suggesting that
DNA–protein binding and gene transcription are affected by the
SNPs. Remarkably, almost all SS risk variants tested (94.4%) had
in silico evidence of regulatory functions including the 3/4 mis-
sense SNPs and the 37/40 intronic SNPs. In addition and accord-
ing to our in silico observations that need further confirmation,
it could be postulated that SS risk variants control DNA-protein
binding leading to the regulation of cell-specific promoters (Pol
II, NF-κB, STATs), enhancers (NF-κB), and insulators (CTCF).
These results also suggest that there is an effect on some common
pathways (NF-κB, STATs) previously described to be affected
in SS (10).
The genetic and epigenetic fine mapping of autoimmune risk
factors was recently performed in 21 AID with the notable excep-
tion of SS (7). In line with our observations, it was observed
that autoimmune risk variants weremostly non-coding (90%) and
map predominantly to H3K27Ac positive immune-cell enhancers
(60%) and promoters (8%). Next, a T cell signature was observed
in nearly all of the AID tested except in lupus and primary billiary
cirrhosis (two AID frequently associated with SS) that present a B
cell signature, and type I diabetes with pancreatic islets. Finally, it
was reported that autoimmune risk factors were enriched within
binding sites for immune-related TFs, such as Pu-1 andNF-κB. As
a consequence, the physiopathology of AID needs to be updated
according to the recent progress in epigenetics (54).
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Some limitations are inherent in this type of study. First,
cells used in the ENCODE program are predominantly cell lines
that are different from primary cells, such as the lymphoblas-
toid GM12878 B cell line, that results from EBV transforma-
tion of peripheral blood mononuclear cell using phytohemag-
glutinin as a mitogen. New results using primary cells, which
are available from the Epigenome Roadmap program further
supports similarities between lymphoblastoid GM12878 B cells
and purified human CD20+ B cells as we observed for the
FAM167A–BLK locus when using the RegulomeDB tool. Sec-
ond, although the ENCODE program is an extensive resource;
the program is limited to certain cell types and DNA bind-
ing elements that limit the interpretation. Third, many SNPs
are in tight genetic linkage and, as a consequence, genetic risk
variants may not be causal, but rather reveal the presence of
a linked SNP that is functionally relevant to the pathogenesis.
Such a situation may be suspected for different SNPs tested
from our selection since the LD analysis has revealed new mis-
sense mutations as well as new gene risk factors that need to be
tested, such as chemokines (CCL7 and CCL11), cytokines (IL2)
and the miRNA4752. Two SNPs in CCL11 have been associ-
ated with germinal center-like structure formation in SS patients
(47), and CCL11 (Eotaxin) circulating levels were reduced in SS
patients (58).
While the function of the protein encoded by FAM167A
is unknown, the tyrosine kinase BLK controls B cell develop-
ment and is activated after B cell receptor engagement. The
FAM167A–BLK locus is associated with several AID, such as SS,
lupus, rheumatoid arthritis, scleroderma, and vasculitis. Among
them, two risk alleles (rs132771113 and rs9222483) are known
to control BLK transcription during B cell development (53,
59). Moreover, by integrating epigenetic fine mapping, we fur-
ther observed that all BLK-associated SS risk variants, including
the two previously described, were all present within epigenetic
marks in B cells. Altogether, this example illustrates the value
of integrating epigenetic resources for investigating the complex
mechanisms by which non-coding risk variants could modulate
gene expression.
Last but not least, the B cell subset identified from our in silico
study deserves several comments. First, B cell qualitative abnor-
malities have been reported in SS with important perturbations
in peripheral blood B cell profiling and B cell migration within
exocrine glands (5, 60). Second, the association between the
incidences of B cells in salivary gland epithelial cells has been
addressed as well as the formation of ectopic germinal centers
and transformation to B cell lymphoma (61). Third, non-HLA
genetic associations in SS are predominantly related to B cell
genes (BTK, CD40, EBF-1 : : :) as we observed in our selection.
Fourth, a recent study reported DNA methylation changes in B
cells and such changes predominate within loci containing SS risk
factors (16). Altogether, these observations provide rationale for
targeting B cells in SS along with the observations that depleting B
cells with Rituximab or targeting BAFF with Belimumab are both
effective (62, 63).
In conclusion, we have tested, as a proof of concept, a novel
approach that integrates both epigenetic information and results
from genomic analysis to further enhance the value of the genetic
risk factors highlighted in complex diseases, such as SS. Future
work needs to be done in order to confirm experimentally the
cellular specificity and the functional role of the characterized
regulatory SNPs. Another consequence is that such approach
could be used to select and/or propose future therapeutic drugs
in SS as epigenetic mechanisms are reversible.
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